Market Cap 1.34B
Revenue (ttm) 23.68M
Net Income (ttm) -318.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,346.11%
Debt to Equity Ratio 2.18
Volume 1,707,000
Avg Vol 2,281,368
Day's Range N/A - N/A
Shares Out 86.14M
Stochastic %K 1%
Beta 0.72
Analysts Strong Sell
Price Target $35.92

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 419 1400
Website: syndax.com
Address:
730 Third Avenue, 9th Floor, New York, United States
sck2
sck2 Sep. 14 at 12:35 PM
$SNDX 🕵️‍♂️💪#12
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 13 at 6:05 PM
Seeking Alpha now notes there are 11 analysts covering $SNDX that provide revenue estimates. 1 new analyst is projecting just north of $3B in FY34 revenues. The other analyst providing FY34 forecasts projects $1.26B. Attached is an updated comparison of SNDX's valuation at $15.55/share or a $1.34B market cap as a multiple of these new analyst revenue estimates. We compared SNDX's profile to 15 peer commercial-stage bios that exited via M&A. Note most SNDX peers were acquired at 0.30X to 0.40X cumulative 10-year revenue forecasts prepared by the acquiree's management/BOD. SNDX trades at 0.08X the highest 10-year analyst revenue estimate. Obviously one has to take such an aggressive revenue forecast with an enormous grain of salt. SNDX trades at 0.12X 10-year consensus estimates. SNDX trades at 0.18X the lowest 10-year analyst estimate (an n of 2 for the last 2 years). Genuine pushback/feedback welcomed? $XBI $NBI $IBB
0 · Reply
sck2
sck2 Sep. 13 at 10:15 AM
0 · Reply
sck2
sck2 Sep. 12 at 9:22 AM
$SNDX ✅💪🚀🚀
0 · Reply
peapope
peapope Sep. 11 at 11:08 PM
0 · Reply
sck2
sck2 Sep. 11 at 3:57 PM
$SNDX 🕵️‍♂️💪🔑🐂
0 · Reply
Polip
Polip Sep. 11 at 2:04 PM
$SNDX $INCY should submit their offer asap unless they want to pay higher. I think 16 is the base price for the premium. The board won't settle for less than 32 today. But with rate cuts coming the premium will be higher ~45
2 · Reply
sck2
sck2 Sep. 11 at 1:53 PM
1 · Reply
sck2
sck2 Sep. 11 at 1:50 PM
$SNDX the long waited Golden Cross about to form as we can see in the square the MA50 blue line about to go over MA200 red line should be good for the target price of $20 - $24 ... lets go $SNDX ✅💪🐂
1 · Reply
sck2
sck2 Sep. 11 at 1:42 PM
$SNDX 🕵️‍♂️💪🐂
0 · Reply
Latest News on SNDX
Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Aug 13, 2025, 6:34 PM EDT - 4 weeks ago

Syndax Pharmaceuticals: A Tale Of Two Drug Launches


Syndax Pharmaceuticals: The Story Brightens

Aug 5, 2025, 12:59 PM EDT - 5 weeks ago

Syndax Pharmaceuticals: The Story Brightens


Syndax Announces Participation in June Investor Conferences

May 29, 2025, 7:00 AM EDT - 3 months ago

Syndax Announces Participation in June Investor Conferences


Syndax Announces Participation in May Investor Conferences

May 8, 2025, 7:00 AM EDT - 4 months ago

Syndax Announces Participation in May Investor Conferences


Syndax Announces Participation in March Investor Conferences

Feb 25, 2025, 7:00 AM EST - 7 months ago

Syndax Announces Participation in March Investor Conferences


Syndax Announces Participation in February Investor Conferences

Jan 30, 2025, 7:00 AM EST - 8 months ago

Syndax Announces Participation in February Investor Conferences


US FDA approves Syndax's blood cancer drug

Nov 15, 2024, 6:26 PM EST - 10 months ago

US FDA approves Syndax's blood cancer drug


Syndax Announces Participation in November Investor Conferences

Nov 1, 2024, 7:00 AM EDT - 11 months ago

Syndax Announces Participation in November Investor Conferences


sck2
sck2 Sep. 14 at 12:35 PM
$SNDX 🕵️‍♂️💪#12
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 13 at 6:05 PM
Seeking Alpha now notes there are 11 analysts covering $SNDX that provide revenue estimates. 1 new analyst is projecting just north of $3B in FY34 revenues. The other analyst providing FY34 forecasts projects $1.26B. Attached is an updated comparison of SNDX's valuation at $15.55/share or a $1.34B market cap as a multiple of these new analyst revenue estimates. We compared SNDX's profile to 15 peer commercial-stage bios that exited via M&A. Note most SNDX peers were acquired at 0.30X to 0.40X cumulative 10-year revenue forecasts prepared by the acquiree's management/BOD. SNDX trades at 0.08X the highest 10-year analyst revenue estimate. Obviously one has to take such an aggressive revenue forecast with an enormous grain of salt. SNDX trades at 0.12X 10-year consensus estimates. SNDX trades at 0.18X the lowest 10-year analyst estimate (an n of 2 for the last 2 years). Genuine pushback/feedback welcomed? $XBI $NBI $IBB
0 · Reply
sck2
sck2 Sep. 13 at 10:15 AM
0 · Reply
sck2
sck2 Sep. 12 at 9:22 AM
$SNDX ✅💪🚀🚀
0 · Reply
peapope
peapope Sep. 11 at 11:08 PM
0 · Reply
sck2
sck2 Sep. 11 at 3:57 PM
$SNDX 🕵️‍♂️💪🔑🐂
0 · Reply
Polip
Polip Sep. 11 at 2:04 PM
$SNDX $INCY should submit their offer asap unless they want to pay higher. I think 16 is the base price for the premium. The board won't settle for less than 32 today. But with rate cuts coming the premium will be higher ~45
2 · Reply
sck2
sck2 Sep. 11 at 1:53 PM
1 · Reply
sck2
sck2 Sep. 11 at 1:50 PM
$SNDX the long waited Golden Cross about to form as we can see in the square the MA50 blue line about to go over MA200 red line should be good for the target price of $20 - $24 ... lets go $SNDX ✅💪🐂
1 · Reply
sck2
sck2 Sep. 11 at 1:42 PM
$SNDX 🕵️‍♂️💪🐂
0 · Reply
sck2
sck2 Sep. 11 at 1:39 PM
$SNDX time for the double top to be toppled ... ✅💪🐂
0 · Reply
sck2
sck2 Sep. 11 at 8:51 AM
$SNDX mentioned with who else $NVDA hahaha - as the best stocks to invest in ... Go $SNDX !!! ✅💪🐂 3 Best Stocks to Buy Now, 9/10/2025, According to Top Analysts
0 · Reply
sck2
sck2 Sep. 11 at 8:45 AM
$SNDX 🕵️‍♂️💪🐂
0 · Reply
Ablade84x
Ablade84x Sep. 11 at 1:12 AM
$SNDX why going down? Disappointed with this price action. I bought in at 15.35 a few weeks ago. FDA Decision on Revuforj soon, october.
1 · Reply
sck2
sck2 Sep. 10 at 11:23 PM
$SNDX ✅💪🔑🐂
0 · Reply
sck2
sck2 Sep. 10 at 8:33 PM
$SNDX next trading zone will be $20 - $22
1 · Reply
Kingjake26
Kingjake26 Sep. 10 at 8:09 PM
$SNDX Added 500 shares :))
0 · Reply
JarvisFlow
JarvisFlow Sep. 10 at 1:00 PM
Stifel has updated their rating for Syndax Pharmaceuticals ( $SNDX ) to Buy with a price target of 44.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 10 at 11:18 AM
$SNDX Information regarding Stifel analyst report on SNDX issued today: https://x.com/CorleoneDon77/status/1965736452362309846 cc: @RonIsWrong
0 · Reply
Polip
Polip Sep. 10 at 10:42 AM
$SNDX stifel PT 44
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 9 at 9:24 PM
$KURA vs $SNDX CEO
1 · Reply
Marcos125
Marcos125 Sep. 9 at 8:05 PM
0 · Reply